ROBERT A. BRODSKY;RICHARD J. JONES;FRANCIS E. O'DONNELL, JR.;LEO LUZNIK;EPHRAIM J. FUCHS;SUSAN BONITZ;CARLOS SANTOS
发明人:
EPHRAIM J. FUCHS,LEO LUZNIK,ROBERT A. BRODSKY,RICHARD J. JONES,FRANCIS E. O'DONNELL, JR.,CARLOS SANTOS,SUSAN BONITZ,FRANCIS E. ODONNELL, JR.
申请号：
US13272864
公开号：
US20120148577A1
申请日:
2011.10.13
申请国别(地区):
US
年份:
2012
代理人:
摘要：
A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.
